Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- NFLX +9.5%, MOSY +6.2%, NVS +2.5%, ELS +1.7%, AMTD +1.6%, PLD+1.2%, LMT +1.2%, ANGO +1.1%, JNJ +0.6%, .
Other news:
- MBRX +17.1% (signs a new technology license agreement with MD Anderson Cancer Center)
- PBYI +8.7% (receives FDA approval for NERLYNX/neratinib in early stage HER2-overexpressed/amplified breast cancer)
- PRAN +8.3% (announces research collaboration with Takeda Pharmaceuticals)
- NVAX +7.9% (to host RSV F vaccine update conference call on July 24 at 4:30pm ET)
- MDGS +7.7% (announces that the Chinese exclusive distribution agreement with Golden Grand has been expanded to account for the increased interest in MUSE systems in China)
- RAD +7.4% (Rite Aid provides supplemental information on impact from Walgreens Boots Alliance Asset Purchase Agreement in response to a number of investor inquiries)
- EGLT +4.9% (Highbridge Capital discloses 9.58% passive stake)
- PRTK +2.6% (announces 'positive' top-line results from a pivotal Phase 3 clinical study comparing omadacycline to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections )
Analyst comments:
- QDEL +2.9% (upgraded to Buy from Hold at Canaccord Genuity)
- INFN +2.3% (initiated with a Buy at Craig Hallum)
- XLNX +1.2% (upgraded to Equal Weight from Underweight at Barclays)
- CMG +1.1% (upgraded to Buy from Hold at Maxim Group )